Peptide News Digest

#Ascend-Phase-2b

2 stories

Industry · View digest

EASD 2026 Milan September 28 to October 2 Sets Up Amylin Analog Data Cluster: AZD6234 APRICUS and ASCEND, Petrelintide ZUPREME-2, Amycretin Follow-Through

The European Association for the Study of Diabetes (EASD) 62nd Annual Meeting in Milan September 28 through October 2, 2026 sets up the September obesity-peptide catalyst calendar and is anchored on the amylin agonist class. AstraZeneca will present Phase 2 APRICUS data (AZD6234 amylin analog monotherapy in obesity) plus the Phase 2b ASCEND readout (AZD6234 plus AZD9550 GLP-1/glucagon dual agonist combination against placebo over 36 weeks, 377 patients). Zealand Pharma and Roche will present petrelintide ZUPREME-2 data (obesity plus type 2 diabetes) with Phase 3 monotherapy initiation planned late 2026. Novo Nordisk will present amycretin (long-acting GLP-1/amylin dual agonist) plus CagriSema follow-through data. The EASD readout window coincides with Roche's Pharma Day September 28 (updates on petrelintide, enicepatide, HM17321). Ascendis Pharma may also provide TransCon CNP achondroplasia updates. The clustered amylin data will position the class for late-2026 and 2027 regulatory and Phase 3 initiation decisions.

Research · View digest

AstraZeneca AZD6234 Amylin Peptide Agonist Phase 2 Data Queued for EASD 2026 in Milan September 28 to October 2

AstraZeneca's AZD6234 (a long-acting selective amylin receptor peptide agonist, weekly subcutaneous, currently in Phase 2 for obesity and type 2 diabetes) is queued for Phase 2 data presentations at the European Association for the Study of Diabetes (EASD) 62nd Annual Meeting in Milan September 28 to October 2, 2026. Trials on deck: APRICUS (obesity monotherapy) primary data 'imminent' per management; ARAY (NCT06851858, AZD6234 in obesity and type 2 diabetes on stable GLP-1 background); and the ASCEND Phase 2b (NCT06862791, 377 patients) that tests AZD6234 monotherapy, AZD9550 (AZ's GLP-1/glucagon dual agonist) monotherapy, and the combination against placebo over 36 weeks. Preliminary characterization suggests body-fat-selective weight loss and a generally tolerable profile. The readouts will provide a direct comparator against Novo Nordisk's CagriSema (semaglutide plus cagrilintide) and Metsera's MET-233i (monthly amylin) and set the near-term valuation frame for AZ's metabolic disease positioning after the $1.2 billion CSPC obesity licensing announced in January.